However, due to rapid degradation by Dipeptidyl peptidase– 4 (DPP-4), stable analogs of GLP-1 such as exendin-4 and liraglutide, as well as DPP-4 inhibitors such as sitagliptin, have been developed for T2D therapy. Here, DPP4 is linked to type 2 diabetes mellitus.